How Semaglutide Drives Weight Loss: The Mechanism

Semaglutide-induced weight loss was initially attributed primarily to appetite suppression through hypothalamic GLP-1 receptors. However, mounting evidence demonstrates that weight loss involves a constellation of mechanisms: reduced food intake, altered meal composition preferences, slowed gastric emptying, improved satiety signalling, and modest changes in energy expenditure. The interplay among these mechanisms, and their relative contributions, varies among individuals, explaining heterogeneity in clinical responses.

The weight loss achieved with semaglutide typically occurs in phases. An initial rapid phase (weeks 0–12) coincides with dose escalation and maximal appetite suppression, producing weight losses of 2–5%. A secondary phase (weeks 12–52) shows continued but slower weight loss as the body adapts to sustained GLP-1 signaling. Understanding these phases has implications for patient counselling regarding expected timelines and for predicting long-term outcomes.

The hypothalamus and nucleus tractus solitarius in the brainstem contain high densities of GLP-1 receptors. Semaglutide-induced activation of these receptors directly suppresses appetite-promoting neurons (particularly those expressing neuropeptide Y and agouti-related peptide) while activating appetite-suppressing neurons (expressing pro-opiomelanocortin and cocaine- and amphetamine-regulated transcript). This neuronal rebalancing shifts energy balance toward reduced food intake. Functional neuroimaging studies demonstrate altered activation in reward-processing regions (e.g., ventromedial prefrontal cortex) in response to food cues during semaglutide treatment, suggesting reduced hedonic drive to eat.

Beyond direct GLP-1 receptor effects, semaglutide promotes secondary changes in appetite-regulating peptides. Reduced caloric intake initiates relative increases in circulating ghrelin (hunger hormone) that would normally promote compensatory eating; however, semaglutide appears to blunt the orexigenic response to ghrelin elevation. Additionally, sustained weight loss enhances circulating leptin signals from reduced adipose tissue, which further supports appetite suppression through leptin signalling in the hypothalamus.

Semaglutide-induced slowing of gastric emptying contributes meaningfully to early satiety and reduced meal size. GLP-1 receptors on enteric neurons in the stomach and duodenum mediate this effect by reducing antral contractions and increasing pyloric sphincter tone. Delayed gastric emptying prolongs nutrient-nutrient contact with intestinal L-cells, enhancing endogenous peptide YY and GLP-1 secretion. These endogenous signals synergize with exogenous semaglutide to further promote satiety and reduce appetite, creating a positive feedback loop.

Semaglutide also appears to influence macronutrient preferences. Observational data from treatment cohorts suggest reduced appetite for high-fat and high-sugar foods, with relative preservation of appetite for protein-rich foods. This shift, if confirmed mechanistically, could favour lean mass preservation during weight loss. The mechanisms underlying macronutrient selectivity remain speculative but may involve GLP-1 signaling effects on reward circuits or alterations in taste processing.

Contrary to initial expectations, semaglutide produces only modest increases in resting energy expenditure (REE)—approximately 5–10% in most studies. This thermogenic effect is considerably smaller than the caloric restriction achieved through appetite suppression and likely reflects direct activation of GLP-1 receptors on metabolic tissues and sympathetic nervous system upregulation. Some preclinical evidence suggests GLP-1 signaling in brown adipose tissue promotes thermogenesis, though clinical verification remains limited.

During semaglutide-induced weight loss, metabolic adaptation occurs—the reduction in REE expected for a given degree of weight loss (approximately 20–25 kcal per kg lost in weight loss-matched controls) is attenuated with semaglutide. This preservation of REE during active weight loss is considered favourable and may contribute to sustained weight maintenance. The mechanisms underlying this metabolic sparing are incompletely understood but may involve reduced metabolic stress signalling or sustained sympathetic activation.

Clinical trials using dual-energy X-ray absorptiometry (DXA) and other body composition imaging techniques demonstrate that semaglutide-induced weight loss is predominantly from fat mass, with relative preservation of lean mass (muscle and bone). In the STEP trials, body composition analysis showed fat mass losses of approximately 80% of total weight loss, while lean mass contributed only 20%—favourable compared to caloric restriction alone, which typically shows 60–70% fat loss and 30–40% lean loss. This preservation may reflect semaglutide's promotion of protein intake preferences and maintenance of anabolic signalling during weight loss.

The preservation of lean mass during semaglutide treatment has important metabolic implications. Lean mass is the primary driver of resting energy expenditure; preservation during weight loss helps maintain REE, potentially reducing the metabolic adaptation that often challenges long-term weight maintenance. This favourable body composition change is cited as a mechanistic advantage of semaglutide over simple caloric restriction.

Despite extensive research, several mechanistic questions remain incompletely answered. The relative contribution of central versus peripheral GLP-1 signaling to weight loss is not precisely quantified in humans. Animal models using central versus peripherally selective GLP-1 agonists suggest both pathways contribute, but the proportional contribution varies by outcome. Additionally, why some individuals achieve dramatic weight loss (>15% baseline) while others show minimal response (<5%) remains unexplained despite comparable GLP-1 receptor agonism. Genetic, microbiotal, metabolic, and psychological factors likely all contribute, but predictive biomarkers are lacking.

The sustainability of weight loss after semaglutide discontinuation is another critical gap. Most observational data show weight regain approaching baseline within 1–2 years of stopping treatment, but whether this reflects loss of pharmacological appetite suppression, neuroadaptation with upregulation of appetite signalling, metabolic adaptation, or behavioral changes is not definitively characterized. Understanding these mechanisms would inform strategies for long-term weight management beyond pharmacotherapy.